Figure 2From: Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy Absolute neutrophil count (ANC) nadir in cycles 1-4 (per-protocol population). Back to article page